Meridian Clinical Research, LLC
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Joyce, Mark
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
REPOSA, NCT06146101: RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

Recruiting
2/3
560
US
IHL-42X Low Dose, Phase 2 Investigational Product - IHL-42X Low dose, IHL-42X High Dose, Phase 2 Investigational Product - IHL-42X High dose, Placebo, Phase 2 Placebo, IHL-42X (Optimal Dose), Phase 3 Investigational Product - IHL-42X, Dronabinol, Phase 3 Comparator - Reference Listed Drug/Dronabinol, Acetazolamide, Phase 3 Comparator - Reference Listed Drug/Acetazolamide, Phase 3 Placebo
Incannex Healthcare Ltd
Obstructive Sleep Apnea
12/26
12/26
NCT05733546: A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Recruiting
2
102
US
Psilocybin, COMP360
COMPASS Pathways
Major Depressive Disorder
10/24
11/24

Download Options